Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

Avidity Biosciences, Inc. (RNA) Change in Account Payables (2024 - 2025)

Avidity Biosciences' Change in Account Payables history spans 2 years, with the latest figure at $2.7 million for Q4 2025.

For Q4 2025, Change in Account Payables rose 236.72% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $8.0 million, changed N/A, while the annual FY2025 figure was $3.8 million, 1188.54% up from the prior year.
Change in Account Payables reached $2.7 million in Q4 2025 per RNA's latest filing, down from $5.8 million in the prior quarter.
In the past five years, Change in Account Payables ranged from a high of $5.8 million in Q3 2025 to a low of -$1.2 million in Q3 2024.